Summary
Taurine is tracked by OSMF as an investigational option for Long COVID; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. ClinicalTrials.gov lists 2 registered trials linking Taurine to Long COVID: 1 is currently recruiting; 1 is active or not yet recruiting. The most advanced is Phase 2 (NCT06721949, sponsored by University of Alberta). It plans or enrolled 300 participants. Registration activity spans 2025 to 2026. The literature layer holds 1 publication for this pair: 1 curated reference. The dated items are from 2024. Items here are search-derived or curated references rather than classified trial reports; treat them as leads to read, not as graded evidence.
Long COVID / PASC is tracked on the OSMF post-viral programme alongside ME/CFS, Long COVID, POTS and MCAS. Across the programme, 423 candidate agents are logged for Long COVID, most of them preliminary; this page isolates the record for one of them.
Evidence table
| Evidence tier | C · Preliminary |
|---|---|
| Evidence score | 13.0 (trials 6.5, literature 1.5, tier 5, approved bonus 0.0) |
| Registered trials | 2 total: 1 recruiting, 1 active / not yet recruiting, 0 completed, 0 other |
| Linked publications | 1 (1 curated reference) |
| Agent type | Other (Other / Unclassified) |
| Development stage (any indication) | Investigational |
| Mechanism / class | Not recorded |
| Data sources | OSMF therapeutic agent database, ClinicalTrials.gov, PubMed |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT06721949 | Taurine Supplementation in Long COVID University of Alberta · 2025 | recruiting | Phase 2 | 300 |
| NCT07682402 | Taurine Supplementation in Adolescents With Post-COVID Condition University of Alberta · 2026 | not yet recruiting | Phase 1 | 30 |
Published literature
- Curated reference (PACVS Evidence Map) Khoramjoo 2024: plasma taurine inversely correlated with PASC severity (148 vs 225 μM); 1.6g/day raised plasma 34μM; mitochondrial tRNA modification +PACVS Evidence Map · 2024
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
Clinical notes: Plasma levels inversely correlated with PASC severity. 1-3g/day raises levels. Mitochondrial + NF-kB rationale. Safe; may help energy/autonomic symptoms. Good mechanistic support, limited direct trials.
Safety: Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing in studies: See linked studies/trials for reported doses and durations; typical protocols vary widely.
Frequently asked questions
Is Taurine approved for Long COVID?
Taurine is tracked by OSMF as an investigational option for Long COVID; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Taurine in clinical trials for Long COVID?
ClinicalTrials.gov lists 2 registered trials linking Taurine to Long COVID: 1 is currently recruiting; 1 is active or not yet recruiting. The most advanced is Phase 2 (NCT06721949, sponsored by University of Alberta). It plans or enrolled 300 participants. Registration activity spans 2025 to 2026.
What does the evidence show for Taurine in Long COVID?
Trials of Taurine in Long COVID are registered but none has completed, so there is no outcome evidence from those studies yet; the record is a signal of research interest. OSMF's existing evidence tier for this pair is C (Preliminary), taken from the OSMF therapeutic agent database, which grades agents by the volume and design of condition-specific evidence rather than by effect size.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-10-07. Page built 2026-10-07.